HRs for prostate cancer by medication status.

Slides:

Advertisements

Similar presentations

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Advertisements

Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults Featured Article: Peter T. Campbell, Ph.D., Christina C. Newton,

Association of blood lipids with AF

Change (with 95% CI) in outcomes by duration of type 2 diabetes

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Baseline characteristics of patients

Diabetes hazard rates by number of visits with reported statin use.

Association between highest tertile for homocysteine and mortality

A: Kaplan-Meier estimate of time to first LLA

Table S1. Inverse correlation between FOXC2 and PP2A/C expression (tested by one-tailed Spearman's nonparametric correlation test, correlation coefficient.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

Cumulative incidences of events, according to glucose-control strategy

Baseline Characteristics According to Sex

Metabolic syndrome—participants with only three components—expected and observed frequencies by age. Metabolic syndrome—participants with only three components—expected.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Exercise PA in MET-hours/week versus total leisure sedentary behavior in hours/day and incident type 2 diabetes mellitus from 2000 to Exercise PA.

CAPP2: Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo. CAPP2: Time to first colorectal.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

Group differences (DKA vs

Incidence of diabetes over time depends on GIS

Relative effects of glucose-control strategy on microvascular disease.

Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

—ROC curves for each simple test compared with NCS (gold standard) plotting the sensitivity versus 1-specificity (the false-positive rate) for different.

Associations between type of MI and incident HF

Shown are cumulative incidence curves of TNNHS and DPT-1 participants who either had DPTRS values >7.00 (A) or dysglycemia (B). Shown are cumulative incidence.

Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

Scatterplot of the RR estimates of type 2 diabetes reported in the 15 included studies, and the pooled RR estimates with corresponding 95% CIs for five.

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Effect of age, sex, race/ethnicity, and obesity on the relation of glycemic measures to Si and AIR. In linear regression models with Si as the dependent.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

ORs for presence of the metabolic syndrome (95% CI) at age 43 years according to leisure-time physical activity and TV viewing (adjusted for sex, socioeconomic.

Crude and adjusted HbA1c change by medication adherence group (proportion of days covered (PDC)) by linear regression, controlling for age, age2, gender,

Relationship between changes in mean fat cell volume and insulin sensitivity (M values) after gastric bypass of obese women. Relationship between changes.

HRs (and 95% CIs) for incident type 2 diabetes for a doubling of total flavonoid (A) and lignan (B) intakes across countries in the InterAct study. HRs.

Difference in average school grades between offspring born to women with type 1 diabetes and the matched control children, by maternal third trimester.

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Adjusted HRs for type 2 diabetes by ferritin, TSAT, serum iron and transferrin levels in men and women. Adjusted HRs for type 2 diabetes by ferritin, TSAT,

HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct study. HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct.

Number of events, the crude incidence rate, and the crude and adjusted HR with 95% CI for the association between pioglitazone use and all-cause mortality.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Example of how quantitative variables displaying a nonhomogeneous risk in visual display were split in high- and low-risk categories. Example of how quantitative.

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

Risk of type 2 diabetes as a function of ABCA1 and ABCG1 genotype in CCHS. Hazard ratios were multifactorially adjusted for age, sex, BMI, hypertension,

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Association of body mass index with all-cause mortality in diabetes and non-diabetes populations, by smoking status. Association of body mass index with.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.

The risk for incident cognitive dysfunction after an episode of severe (A) or nonsevere (B) hypoglycemia with and without accounting for the competing.

RR (with 95% CI) of total mortality (multivariate-adjusted) by duration of smoking cessation among diabetic women. RR (with 95% CI) of total mortality.

Manhattan plot of 11,628 m/z features comparing participants who developed incident T2D versus those who did not. Manhattan plot of 11,628 m/z features.

Cases of and deaths from prostate cancer, with associated age-standardized incidence and mortality (per men), among Canadian men aged 45 years.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

The ADA research program supports research across the broad spectrum of diabetes types and research topic areas (proportions of 2011 allocations in dollars).

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Presentation transcript:

HRs for prostate cancer by medication status. HRs for prostate cancer by medication status. Results are shown for Cox proportional hazards model adjusting for all variables listed in Table 2 that have a P value <0.05. The 95% CIs are shown as vertical lines on bars. The number of incident PCa cases and total cohort members for each group is provided in Table 1. The HR of the left-most reference group refers to the group on sulfonylurea only and is provided for orientation purposes. Donna M. Lehman et al. Dia Care 2012;35:1002-1007 ©2012 by American Diabetes Association